Literature DB >> 1914547

Legionella pneumophila. A cause of severe community-acquired pneumonia.

V Falcó1, T Fernández de Sevilla, J Alegre, A Ferrer, J M Martínez Vázquez.   

Abstract

In a prospective study of community-acquired pneumonias, 30 patients were diagnosed with Legionnaires' disease in 15 months. Clinical, laboratory and radiologic features of these patients are reviewed and compared with those who have pneumococcal pneumonia. Alcoholism, history of smoking, previous antimicrobial therapy, gastrointestinal and neurologic manifestations, elevations of serum transaminases, alkaline phosphatase and creatinine levels were more frequent in pneumonia due to Legionella pneumophila than in pneumococcal pneumonia. The presence of respiratory failure and radiologic progression were common findings that suggested L pneumophila as the etiologic agent of a community-acquired pneumonia. Development of respiratory failure was associated with involvement of several lobes and isolation of L pneumophila in any specimen. In 21 of 30 patients with Legionnaires' disease, L pneumophila was isolated from respiratory specimens. Overall mortality was 10 percent, but it increased to 27 percent in patients not treated with erythromycin initially.

Entities:  

Mesh:

Year:  1991        PMID: 1914547     DOI: 10.1378/chest.100.4.1007

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  29 in total

1.  BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.

Authors: 
Journal:  Thorax       Date:  2001-12       Impact factor: 9.139

2.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

3.  Legionella Pneumophilla Infection Masquerading as Acute Cholecystitis.

Authors:  Dimitrios Anyfantakis; Vasiliki Krietsepi; Aggeliki Damianaki; Emmanouil K Symvoulakis; Argiro Gogou; Eirini Pasparaki; Serafim Kastanakis
Journal:  Maedica (Buchar)       Date:  2015-09

4.  Clarithromycin in the Treatment of Legionella pneumophila Pneumonia Associated with Multiorgan Failure in a Previously Healthy Patient.

Authors:  L Gallelli; V Gioffrè; G Vero; A Gallelli; F Roccia; S Naty; G Pelaia; A Capano; A Loiacono; G De Sarro; R Maselli
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

5.  Diagnostic value of bronchoalveolar lavage in patients with opportunistic and nonopportunistic bacterial pneumonia.

Authors:  K Dalhoff; J Braun; H Hollandt; R Lipp; K J Wiessmann; R Marre
Journal:  Infection       Date:  1993 Sep-Oct       Impact factor: 3.553

Review 6.  Current and emerging Legionella diagnostics for laboratory and outbreak investigations.

Authors:  Jeffrey W Mercante; Jonas M Winchell
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

7.  Simplified quantitative assay system for measuring activities of drugs against intracellular Legionella pneumophila.

Authors:  F Higa; N Kusano; M Tateyama; T Shinzato; N Arakaki; K Kawakami; A Saito
Journal:  J Clin Microbiol       Date:  1998-05       Impact factor: 5.948

Review 8.  The role of Streptococcus pneumoniae in community-acquired pneumonia among adults in Europe: a meta-analysis.

Authors:  M H Rozenbaum; P Pechlivanoglou; T S van der Werf; J R Lo-Ten-Foe; M J Postma; E Hak
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-12-14       Impact factor: 3.267

9.  Acute Legionella pneumophila infection masquerading as acute alcoholic hepatitis.

Authors:  Jonathan Michael Hunter; Julian Chan; Angeline Louise Reid; Chistopher Tan
Journal:  BMJ Case Rep       Date:  2013-01-25

10.  Legionnaires' disease at a Dutch flower show: prognostic factors and impact of therapy.

Authors:  Kamilla D Lettinga; Annelies Verbon; Gerrit-Jan Weverling; Joop F P Schellekens; Jeroen W Den Boer; Ed P F Yzerman; Jacobus Prins; Wim G Boersma; Ruud J van Ketel; Jan M Prins; Peter Speelman
Journal:  Emerg Infect Dis       Date:  2002-12       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.